Clinical Trial Detail

NCT ID NCT04356729
Title A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Elizabeth Buchbinder
Indications

skin melanoma

Therapies

Atezolizumab + Bevacizumab

Age Groups: adult senior

No variant requirements are available.